GHK-Cu (Copper Tripeptide-1)
← Back to LibraryCompound Profile
GHK-Cu (Copper Tripeptide-1) is reviewed here for tissue repair and recovery.
Research Summary
Safety notices, literature searches, limited protocol data
Tissue repair, Injury recovery, Gut support
Target context: MMP; DNA Repair
Limited, unclear, or affected by safety flags.
Claims need extra caution because evidence is thin or safety flags apply.
Route(s)
Subcutaneous
Typical dose
1mg
Dosing window
Anytime
Receptor / target
MMP; DNA Repair
Properties
Not listed
Pre-mixed
No
How GHK-Cu is studied in skin and tissue
GHK-Cu is a copper peptide researched for skin, collagen, hair, and wound-repair pathways.
Scalp and Hair — Hair Follicles
Limited human and lab dataStudied for follicle support and a healthier scalp environment. Evidence for hair growth is still limited.
Face — Skin and Collagen
Topical and lab researchStudied for collagen, skin firmness, elasticity, and visible signs of aging.
Shoulder or Upper Chest — Tissue Repair
Lab and wound-repair researchStudied for collagen rebuilding, fibroblast activity, and wound repair.
Small Scar Area — Skin Recovery
Skin-remodelling researchStudied for skin remodelling and the repair process after damage.
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 1mg 1x Daily | 5 Days on, 2 Days Off. Rotate injection sites frequently due to bruising. |
| Weeks 5-8 | 1.5mg 1x Daily | 5 Days on, 2 Days Off. Rotate injection sites frequently due to bruising. |
| Weeks 9-12+ | 2mg 1x Daily | 5 Days on, 2 Days Off. Rotate injection sites frequently due to bruising. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative 1: The BPC Blend Buffer
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 1.5mg GHK-Cu + 250mcg BPC-157 | Pulling BPC-157 into the same syringe as GHK-Cu acts as a buffer, almost entirely eliminating the severe injection site sting. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative 2: 8-Week Daily Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 1mg 1x/day | 7 days/week. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | FDA safety-risk context or unapproved compounded-use warning is attached to this entry; no FDA-approved human label was identified for this compound/page context. |
|---|---|
| Where studied | Studied mainly in wound, tendon, ligament, gut, inflammation, angiogenesis, and tissue-repair models; human evidence varies widely by compound. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records; NIH ODS fact sheets |
| Target and route context | Target/receptor: MMP; DNA Repair. Route(s): Subcutaneous. Dosing window on page: Anytime. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty. |
Source-linked findings
- GHK-Cu has dermatology, wound-healing, extracellular-matrix, and copper-biology literature, with NIH copper guidance relevant to systemic copper exposure.
- Topical/cosmetic evidence does not prove safety or efficacy for injectable protocols.
- FDA lists injectable GHK-Cu among withdrawn nominated bulk substances with limited human safety data. Copper toxicity concerns should be framed around total elemental copper, route, and copper-handling disorders; reflex zinc supplementation is not supported and excess zinc can reduce copper status.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-4, 1mg 1x Daily; Alternative 1: The BPC Blend Buffer: Weeks 1-8, 1.5mg GHK-Cu + 250mcg BPC-157.
- Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty.
- Monitor injury diagnosis, rehab loading, infection, anticoagulant use, abnormal vessel growth, cancer history, and injection-site sterility.
Selected medical sources
Independent evidence
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Wilson's disease or other genetic copper metabolism disorders: the copper component of GHK-Cu bypasses normal hepatic copper regulation; copper accumulation in subjects with impaired copper transport (ATP7B mutations) is a serious risk.
- Known copper hypersensitivity or copper allergy: systemic injection of a copper complex in a hypersensitive subject may provoke significant immune reactions.
- Active malignancy: GHK-Cu promotes angiogenesis via VEGF/VEGFR2 upregulation; while preclinical data suggests anti-metastatic gene regulation, the pro-angiogenic mechanism remains a contraindication in subjects with active tumors.
- Pregnancy: no human safety data; copper homeostasis is tightly regulated during fetal development; avoid.
- Breastfeeding: no established safety data.
- Known hypersensitivity to GHK-Cu or peptide excipients.
- Copper-chelating drugs (for example penicillamine or trientine) and pharmacologic zinc used specifically to lower copper may interfere with the active copper complex. Do not add zinc simply to 'balance' GHK-Cu; high-dose zinc can lower copper status and should be based on labs or clinician guidance. Source-supported caution
- Hemochromatosis or iron overload disorders: impaired metal metabolism may affect copper handling.
- Individuals with elevated baseline serum copper levels: risk of copper toxicity at systemic injectable doses.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Severe Post-Injection Pain (PIP): the defining adverse effect of subcutaneous GHK-Cu; caused by the copper ion reacting with subcutaneous tissue; characterized by burning, stinging, redness, and welts at the injection site; intensity varies by concentration, volume, and injection location; nearly eliminated by co-injecting with BPC-157.
- Bruising and hematoma formation at injection sites: particularly with daily protocols; mandatory site rotation mitigates this but does not eliminate it.
- Local redness and induration: tissue response to copper deposition; resolves between injection sessions; the 5-on/2-off schedule provides recovery time.
- Copper toxicity fear check: adult oral copper UL is 10 mg/day from food and supplements, and GHK-Cu is not pure copper (4 mg is roughly under 1 mg elemental copper). That does not make injection risk zero: route, total copper exposure, liver disease, Wilson's disease, elevated baseline copper, and chronic high-dose use still matter. Source-supported caution
- "Copper uglies": a rare paradoxical effect where excessive MMP-1 stimulation at high concentrations causes collagen fragmentation rather than synthesis, resulting in apparent skin quality degradation; primarily documented anecdotally in topical overuse; not formally documented at injectable doses.
- Mild systemic fatigue: occasionally reported in first 1-2 weeks of use; likely related to initial tissue remodeling signal load.
- Headache: uncommon; possibly related to VEGF-mediated vasodilation.
- Temporary melanin increase at injection sites: tyrosinase activation from copper delivery can produce local hyperpigmentation; resolves over weeks after cessation.
- Nausea: rare; may be copper-related at higher doses.
- Potential MMP overactivation at supraphysiological concentrations: theoretical; context-dependent MMP regulation can shift from constructive to destructive at excessive doses.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: